Gemini Therapeutics Probability of Future Stock Price Finishing Over 22.67
| GMTXDelisted Stock | USD 17.95 0.05 0.28% |
Gemini |
Gemini Therapeutics Target Price Odds to finish over 22.67
The tendency of Gemini Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 22.67 or more in 90 days |
| 17.95 | 90 days | 22.67 | near 1 |
Based on a normal probability distribution, the odds of Gemini Therapeutics to move over $ 22.67 or more in 90 days from now is near 1 (This Gemini Therapeutics probability density function shows the probability of Gemini Stock to fall within a particular range of prices over 90 days) . Probability of Gemini Therapeutics price to stay between its current price of $ 17.95 and $ 22.67 at the end of the 90-day period is about 17.67 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.55 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Gemini Therapeutics will likely underperform. Additionally Gemini Therapeutics has an alpha of 0.3602, implying that it can generate a 0.36 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta). Gemini Therapeutics Price Density |
| Price |
Predictive Modules for Gemini Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Gemini Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Gemini Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Gemini Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Gemini Therapeutics is not an exception. The market had few large corrections towards the Gemini Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Gemini Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Gemini Therapeutics within the framework of very fundamental risk indicators.α | Alpha over NYSE Composite | 0.36 | |
β | Beta against NYSE Composite | 1.55 | |
σ | Overall volatility | 1.25 | |
Ir | Information ratio | 0.06 |
Gemini Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Gemini Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Gemini Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Gemini Therapeutics is not yet fully synchronised with the market data | |
| Gemini Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (71.87 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Gemini Therapeutics currently holds about 108.66 M in cash with (59.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.51. | |
| Over 88.0% of the company shares are owned by institutional investors |
Gemini Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Gemini Stock often depends not only on the future outlook of the current and potential Gemini Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Gemini Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 15.1 M | |
| Cash And Short Term Investments | 136.6 M |
Gemini Therapeutics Technical Analysis
Gemini Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Gemini Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Gemini Therapeutics. In general, you should focus on analyzing Gemini Stock price patterns and their correlations with different microeconomic environments and drivers.
Gemini Therapeutics Predictive Forecast Models
Gemini Therapeutics' time-series forecasting models is one of many Gemini Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Gemini Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Gemini Therapeutics
Checking the ongoing alerts about Gemini Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Gemini Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Gemini Therapeutics is not yet fully synchronised with the market data | |
| Gemini Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (71.87 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Gemini Therapeutics currently holds about 108.66 M in cash with (59.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.51. | |
| Over 88.0% of the company shares are owned by institutional investors |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Gemini Stock
If you are still planning to invest in Gemini Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gemini Therapeutics' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |